Stock Track | Hinge Health Plunges 12.26% Pre-Market Despite Q3 Beat as Growth Concerns Overshadow Results

Stock Track11-05

Shares of Hinge Health, Inc. (HNGE) tumbled 12.26% in pre-market trading on Wednesday, extending a sharp decline that began after the company's third-quarter earnings release. This significant drop comes despite the company reporting better-than-expected results, highlighting investors' focus on concerns about future growth prospects and profitability sustainability.

For the third quarter, Hinge Health reported a loss of $0.02 per share, significantly better than the FactSet consensus estimate of a $0.15 loss. Revenue surged 53% year-over-year to $154.2 million, surpassing analysts' expectations. The company also highlighted strong client growth, with the number of clients increasing 25% to 2,560 compared to the same period last year. Additionally, Hinge Health raised its full-year 2025 revenue guidance to between $572 million and $574 million, representing 47% growth at the midpoint.

However, the market's negative reaction suggests that investors are more concerned about the company's decelerating growth rate and the sustainability of its profitability. While the 53% revenue growth is impressive, it marks a slowdown from previous quarters. The company's guidance for the fourth quarter implies further deceleration, with projected revenue growth of 33% at the midpoint of the $155 million to $157 million range. This trend of slowing growth, coupled with concerns about the sustainability of profitability improvements in light of substantial stock-based compensation expenses, appears to be driving the negative market reaction, overshadowing the otherwise strong financial results and recent analyst target price increases.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment